Drug Trial Radar · NCT02274558
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
Last checked: Nov 20, 2026Latest source record: Jul 11, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
234
Actual
Start
Oct 2014
Primary completion
Sep 2015
Study completion Jul 2016
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Oct 24, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
Conditions
- Tardive Dyskinesia
Interventions
NBI-98854Drug
NBI-98854 40 mg capsules
PlaceboDrug
NBI-98854 placebo capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6Time frame: Baseline and Week 6
Locations
54 sites in 3 countries. Site status is shown where the registry gives one.
Site not named
Little Rock, Arkansas
Site not named
Anaheim, California
Site not named
Glendale, California
Site not named
Irvine, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
National City, California
Site not named
Norwalk, California
Site not named
Oakland, California
Site not named
Oceanside, California
Site not named
San Bernardino, California
Site not named
San Diego, California
Site not named
Torrance, California
Site not named
Bradenton, Florida
Site not named
Hialeah, Florida
Site not named
Kissimmee, Florida
Site not named
Leesburg, Florida
Site not named
Maitland, Florida
Site not named
Miami, Florida
Site not named
North Miami, Florida
Site not named
Chicago, Illinois
Site not named
Oak Brook, Illinois
Site not named
Shreveport, Louisiana
Site not named
Baltimore, Maryland
Site not named
Glen Burnie, Maryland
Site not named
Worcester, Massachusetts
Site not named
Flowood, Mississippi
Site not named
St Louis, Missouri
Site not named
Lincoln, Nebraska
Site not named
Amherst, New York
Site not named
Cedarhurst, New York
Site not named
Rochester, New York
Site not named
Durham, North Carolina
Site not named
Pinehurst, North Carolina
Site not named
Dayton, Ohio
Site not named
Shaker Heights, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Conshohocken, Pennsylvania
Site not named
Norristown, Pennsylvania
Site not named
Phoenixville, Pennsylvania
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.